Madrigal Pharmaceuticals (MDGL) Set to Announce Earnings on Monday

Madrigal Pharmaceuticals (NASDAQ:MDGLGet Rating) will be releasing its earnings data before the market opens on Monday, May 9th. Analysts expect Madrigal Pharmaceuticals to post earnings of ($3.75) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Madrigal Pharmaceuticals (NASDAQ:MDGLGet Rating) last issued its quarterly earnings data on Thursday, February 24th. The biopharmaceutical company reported ($3.78) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.92) by $0.14. On average, analysts expect Madrigal Pharmaceuticals to post $-15 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

NASDAQ MDGL opened at $70.00 on Monday. The company has a 50-day moving average price of $89.65 and a two-hundred day moving average price of $83.35. Madrigal Pharmaceuticals has a 52 week low of $52.33 and a 52 week high of $142.62.

Several hedge funds have recently modified their holdings of the company. Royal Bank of Canada raised its stake in shares of Madrigal Pharmaceuticals by 2.3% in the 3rd quarter. Royal Bank of Canada now owns 7,873 shares of the biopharmaceutical company’s stock worth $629,000 after buying an additional 174 shares in the last quarter. Legal & General Group Plc grew its holdings in Madrigal Pharmaceuticals by 2.9% during the fourth quarter. Legal & General Group Plc now owns 9,524 shares of the biopharmaceutical company’s stock worth $807,000 after acquiring an additional 270 shares during the period. MetLife Investment Management LLC raised its position in Madrigal Pharmaceuticals by 14.3% in the fourth quarter. MetLife Investment Management LLC now owns 4,214 shares of the biopharmaceutical company’s stock worth $357,000 after acquiring an additional 527 shares in the last quarter. Marshall Wace LLP acquired a new stake in Madrigal Pharmaceuticals in the 4th quarter valued at about $52,000. Finally, California State Teachers Retirement System boosted its position in shares of Madrigal Pharmaceuticals by 4.4% during the 4th quarter. California State Teachers Retirement System now owns 14,874 shares of the biopharmaceutical company’s stock valued at $1,260,000 after purchasing an additional 624 shares in the last quarter. Institutional investors own 81.83% of the company’s stock.

Several equities analysts have recently issued reports on the company. Zacks Investment Research downgraded Madrigal Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday. JMP Securities reiterated a “buy” rating and set a $220.00 price target on shares of Madrigal Pharmaceuticals in a research report on Monday, February 7th. Finally, StockNews.com began coverage on Madrigal Pharmaceuticals in a report on Thursday, March 31st. They set a “sell” rating on the stock. Two equities research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $163.43.

Madrigal Pharmaceuticals Company Profile (Get Rating)

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-Ã agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis.

Recommended Stories

Earnings History for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.